https://naveris.com/press/
Press Releases | Naveris
press releasesnaveris
https://naveris.com/
Naveris | Transformative Technologies for Early Cancer Detection
Naveris develops highly sensitive blood tests that identify viral cancers significantly earlier than scans or traditional biopsies.
early cancernaveristransformativetechnologiesdetection
https://www.labmedica.com/industry-news/articles/294810098/caredx-expands-precision-oncology-portfolio-with-naveris-acquisition.html
CareDx Expands Precision Oncology Portfolio with Naveris Acquisition - Industry News - Labmedica.com
Apr 29, 2026 - CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
precision oncologyindustry newscaredxexpandsportfolio
https://naveris.com/contact/
Contact Us at Naveris.com | Early Cancer Detection
Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.
early cancerusnaverisdetection
https://naveris.com/notice-of-privacy-practices-under-hipaa/
NOTICE OF PRIVACY PRACTICES UNDER HIPAA | Naveris
THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT UNITED STATES RESIDENTS MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION.
privacy practicesnoticehipaanaveris
https://naveris.com/in-the-news/
Naveris in the News | Transforming Cancer Detection
Naveris develops blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.
naverisnewstransformingcancerdetection
https://naveris.com/about/
About | Naveris
Naveris has developed highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of res ...
naveris
https://naveris.com/?blackhole=c15866191c
Naveris | Transformative Technologies for Early Cancer Detection
Naveris develops highly sensitive blood tests that identify viral cancers significantly earlier than scans or traditional biopsies.
early cancernaveristransformativetechnologiesdetection
https://www.aiqixie.com/ivdchangjia/5191.html
Naveris - 美国HPV驱动癌症液体活检企业 | CareDx拟收购_IVD厂家_爱器械
May 8, 2026 - Naveris是全球领先的液体活检企业, 2017年创立于美国马萨诸塞州, 核心产品NavDx基于TTMV技术检测HPV驱动癌症MRD. 2025年收入3400万美元, 2026年4月CareDx宣布以最高2.6亿美元收购, 预计Q3完成交割.
naveris
https://naveris.com/leadership/
Leadership | Naveris
Dr. Gupta earned his bachelor’s degree in Mathematics from the University of Chicago and a PhD in Cancer Biology from MIT. Dr. Gupta was a member of the Whi ...
leadershipnaveris
https://naveris.com/physicians/
Information for Physicians | Naveris | Early Cancer Detection
Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.
early cancerinformationphysiciansnaverisdetection
https://naveris.com/laboratory/
Laboratory | Naveris
Naveris laboratory is licensed with the Clinical Laboratory Improvement Amendments (CLIA) from the Centers for Medicare and Medicare Services (CMS) and is a ...
laboratorynaveris
https://naveris.com/what-is-navdx/
WHAT IS NavDx®? | Naveris
NavDx is the first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.
naveris